Ibrutinib as Initial Therapy for Patients with Chronic Lymphocytic Leukemia

BACKGROUND: Chronic lymphocytic leukemia (CLL) primarily affects older persons who often have coexisting conditions in addition to disease-related immunosuppression and myelosuppression. We conducted an international, open-label, randomized phase 3 trial to compare two oral agents, ibrutinib and chl...

Cijeli opis

Spremljeno u:
Bibliografski detalji
Izdano u:N Engl J Med
Glavni autori: Burger, Jan A., Tedeschi, Alessandra, Barr, Paul M., Robak, Tadeusz, Owen, Carolyn, Ghia, Paolo, Bairey, Osnat, Hillmen, Peter, Bartlett, Nancy L., Li, Jianyong, Simpson, David, Grosicki, Sebastian, Devereux, Stephen, McCarthy, Helen, Coutre, Steven, Quach, Hang, Gaidano, Gianluca, Maslyak, Zvenyslava, Stevens, Don A., Janssens, Ann, Offner, Fritz, Mayer, Jiří, O'Dwyer, Michael, Hellmann, Andrzej, Schuh, Anna, Siddiqi, Tanya, Polliack, Aaron, Tam, Constantine S., Suri, Deepali, Cheng, Mei, Clow, Fong, Styles, Lori, James, Danelle F., Kipps, Thomas J.
Format: Artigo
Jezik:Inglês
Izdano: 2015
Teme:
Article
Online pristup:https://ncbi.nlm.nih.gov/pmc/articles/PMC4722809/
https://ncbi.nlm.nih.gov/pubmed/26639149
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1056/NEJMoa1509388
Oznake: Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!

Similar Items